After achieving financial stability and the successful launch of its lead asthma product flutiform, the board of Skyepharma Plc has agreed to merge with Vectura Group Plc, another developer of respiratory products. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
